Skip to main navigation
  • Back to SpringWorksTx.com
  • Investors & Media
  • Contact Us
  • Linkedin
  • Twitter
SpringWorks
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • Investor FAQs
    • Investor Contacts
    • Email Alerts
  • Investors + Media
  • Medical Professionals
  • Contact Us
  • Linkedin
  • Twitter

Investor Relations

The full potential of targeted oncology is waiting to be unlocked.

Corporate Profile

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines to help patients suffering from devastating cancers live longer, better lives.
View Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

30 May 2023
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
25 May 2023
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
24 May 2023
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
11 May 2023
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
View All

Upcoming Events

There are no upcoming events scheduled at this time.
View All Events

Featured Reports & Presentations

SpringWorks Phase 3 DeFi Trial Results Presented at ESMO 2022 6.7 MB
SpringWorks Therapeutics R&D Day 7.2 MB

Featured Pages

Blue background
Corporate Governance
Corporate Governance
Teal Background
Financial Information
Financial Information
Blue background
Stock Information
Stock Information
Teal Background
Investor Resources
Investor Resources

Springworks - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contacts

Springworks Logo

Social Links

  • linkedin
  • twitter
Footer 1
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • Partners & Collaborators
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
Footer 2
  • Pipeline
    • Nirogacestat
    • Mirdametinib
    • Clinical Trials
    • Investigator-Initiated Research
  • Careers
    • View Opportunities
    • Desmoid Tumor Commercial Team
Footer 3
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access
  • Contact
Footer 4
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor Resources

© 2023 SpringWorks Therapeutics. All rights reserved.

Copyright Links

  • Privacy Policy
  • Terms of Use
  • Cookie Policy